Approximately 25% to 30% of cases of gastroparesis are not idiopathic and are not secondary to diabetes or postoperative gastric motor dysfunction. Etiologies in such instances include disorders ...

It is driven by rising diabetes rates. The global gastroparesis drugs market is set to grow by $1.42b from 2024 to 2028, with ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

Management of patients with gastroparesis is challenging. Although the syndrome has multiple causes and knowledge of the pathophysiology and natural history is far from complete, a number of ...

Report on how AI is redefining market landscape - The global gastroparesis drugs market size is estimated to grow by USD 1.42 ...

While you may have never heard of it, gastroparesis is a chronic condition that affects the way food passes through the ...

Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing ...

“I have a lot of pain in my stomach," she said. "I have a lot of pain in my chest. I feel lots of nausea." Smoot suffers from ...

The following is a summary of “Brain Fog in Gastrointestinal Disorders: Small Intestinal Bacterial Overgrowth, Gastroparesis, ...

Evoke Pharma Inc (NASDAQ:EVOK) shares are trading higher Monday after the company presented GLP-1 data for users with ...

Evoke Pharma Inc. (EVOK) and Eversana Life Science Services, LLC. announced statistically significant comparative data on its study ...

The real-world retrospective study evaluated the impact of GIMOTI (metoclopramide nasal spray) in patients with diabetic gastroparesis (DGP) who were concurrently using GLP-1 receptor agonists.